Tumors: 12 Car-T therapies – Liguria in one year at San Martino di Genova

Report as of June 24. In October out of 17 treated 10 in remission

(ANSA) – GENOA, 02 DEC – One year (24 June) from the beginning of the use of Car-T therapies, personalized treatments against cancer, the stem cell transplantation and cell therapy center of the San Martino Polyclinic hospital performed 12 infusions, making it the fourth center in Italy out of the 22 activated for these therapies. This was announced by the institute in a note, after a summary report on the activity carried out by the center directed by Emanuele Angelucci.

The ‘Car-T’ are personalized cancer therapies that directly enhance the patient’s immune system to make it able to recognize and destroy cancer cells (immunotherapies). And they offer a treatment strategy with concrete chances of recovery for patients who might otherwise run out of treatment options with real chances of recovery.

In Italy today Car-T therapy is indicated in pediatric patients and young adults up to 25 years with refractory acute B-cell lymphoblastic leukemia, in post-transplant recurrence or in second or further relapse, adult patients with diffuse large B cell lymphoma , relapsed or refractory after two or more lines of systemic therapy; in adult patients with relapsed or refractory diffuse large B-cell lymphoma or primary B-cell lymphoma of the mediastinum after two or more lines of systemic therapy.

As of October this year, of the 17 patients treated with Car-T at the San Martino center, 15 had diffuse large B-cell lymphoma and 2 had primary mediastinal lymphoma. Their response to Car-T treatment was: for 10 patients complete remission, for 1 patient partial remission, for 6 patients disease progression. An overall survival of 71.7% and a progression-free survival of 63.3% are estimated at 20 weeks post infusion. (HANDLE).